INTRODUCTION {#s1}
============

Inherited ion channel mutations are an important cause of sinoatrial node (SAN) dysfunction in the young ([@DMM037994C41]). The recent identification of rare genetic variants in genes encoding G-protein β (Gβ) subunits has expanded the repertoire of causal genes involved in SAN dysfunction beyond the previously described ion channel subunit genes ([@DMM037994C20]; [@DMM037994C50]; [@DMM037994C38]; [@DMM037994C43]). Gβ subunits are components of heterotrimeric G-protein complexes that mediate G protein-coupled receptor signaling, which is involved in many processes, including slowing of heart rate (HR). Acetylcholine (ACh), released from post-ganglionic parasympathetic neurons, binds to M~2~ muscarinic receptors on pacemaker cells and atrial myocytes, triggering activation of heterotrimeric G-proteins that dissociate into Gα-GTP and Gβγ subunits. Of central importance is the effect of the Gβγ complex on the G protein-coupled inwardly rectifying K^+^ (GIRK) channel, which underlies the ACh-activated K^+^ channel \[I(KACh); also known as I~K,ACh~\]. I(KACh) is predominantly expressed in pacemaker cells and atrial myocytes ([@DMM037994C7]) and is a heterotetramer consisting of Kir3.1 (encoded by *KCNJ3*) and Kir3.4 (encoded by *KCNJ5*) ion channel subunits ([@DMM037994C15]). The Gβγ complex activates I(KACh) ([@DMM037994C45]), which, due to its permeability for K^+^ ions and inwardly rectifying properties ([@DMM037994C33]), results in membrane potential hyperpolarization and slowing of diastolic depolarization in SAN cells, thereby decreasing spontaneous activity ([@DMM037994C6]).

Recently, we and others reported mutations in *GNB5*, encoding Gβ5, as a cause of an autosomal recessive multisystem disorder including severe bradycardia at young age, necessitating pacemaker implantation ([@DMM037994C20]; [@DMM037994C38]; [@DMM037994C43]). As opposed to the other Gβ subunits, Gβ5 has an inhibitory effect on GIRK channels, thereby dampening the parasympathetic response, an effect that involves interaction with regulator of G-protein signaling (RGS) proteins ([@DMM037994C16]; [@DMM037994C47]). In patients carrying pathogenic variants in *GNB5*, the maximal HR during exercise is unaffected, whereas severe bradycardia occurs at rest, indicating a relation between the mutant *GNB5* and parasympathetic state ([@DMM037994C20]). Of the eight families described, the majority harbored recessive loss-of-function variants (i.e. nonsense, splice-site and frameshift) ([@DMM037994C20]; [@DMM037994C38]; [@DMM037994C43]), whereas the recessive missense variant c.242C\>T p.S81L (NM_006578.3, rs761399728) was found in two independent families ([@DMM037994C20]). This missense variant is a low-frequency variant in individuals of Latin descent (minor allele frequency ∼3.2×10^−4^), where 1 in ∼1500 individuals is a heterozygous carrier ([@DMM037994C17]).

The mechanism by which inherited genetic variation in *GNB5* causes excessive bradycardia remains unclear. By CRISPR/Cas9-based genome editing, we here generated an isogenic series of human induced pluripotent stem cell (hiPSC) lines (wild type, heterozygous and homozygous for Gβ5-S81L), which we differentiated into cardiomyocytes (hiPSC-CMs) that robustly express the I(KACh) channel by applying a retinoic acid (RA)-based protocol. We demonstrate that, in the homozygous state, the S81L variant results in an increased ACh-activated potassium current (*I*~K,ACh~) density and in excessive slowing of spontaneous activity upon stimulation with the cholinergic agonist carbachol (CCh). We also show reversibility of the phenotype by a specific blocker of I(KACh) (XEN-R0703), both in homozygous Gβ5-S81L hiPSC-CMs and *in vivo* in a zebrafish *gnb5*-knockout model, thus presenting proof of principle for pharmacological treatment of bradycardia as a consequence of genetic variants in *GNB5*.

RESULTS {#s2}
=======

Generation of Gβ5-S81L heterozygous and homozygous hiPSCs {#s2a}
---------------------------------------------------------

To evaluate the electrophysiological consequences of the Gβ5-S81L variant, we introduced it into a control hiPSC line ([@DMM037994C8]) by means of CRISPR/Cas9-based genome editing, generating an isogenic series consisting of wild type, heterozygous and homozygous Gβ5-S81L hiPSC lines (hereafter annotated as WT, S81L^het^ and S81L^homo^, respectively) ([Fig. S1A-C](Fig. S1A-C)). All cell lines maintained expression of the pluripotency markers TRA1-81, OCT4, NANOG and SSEA4 ([Fig. S1D-E](Fig. S1D-E), [Table S2](Table S2)), exhibited a normal karyotype ([Fig. S1F,G](Fig. S1F,G)) and showed unmodified sequences at candidate gRNA off-target loci ([Table S3](Table S3)). Data were generated from one clone per genotype. Relevant results were also confirmed in a second S81L^homo^ clone.

Generation of hiPSC-CMs in the presence of RA results in functional *I*~K,ACh~ {#s2b}
------------------------------------------------------------------------------

To study the effect of the Gβ5-S81L variant on *I*~K,ACh~, we differentiated the three isogenic hiPSC lines into hiPSC-CMs using an RA-based differentiation protocol that promotes acquisition of atrial-like fate with robust expression of I(KACh). In line with our previous observations ([@DMM037994C5]; [@DMM037994C24]), we found that, in WT hiPSC-CMs, the atria-enriched transcripts *NPPA* and *NR2F2* were upregulated upon RA treatment, as was the transcript of *KCNJ3*, encoding Kir3.1 ([Fig. 1](#DMM037994F1){ref-type="fig"}A). In both DMSO- and RA-treated WT hiPSC-CMs, we observed spontaneously active cells. Spontaneous activity is a consistent finding in hiPSC-CMs ([@DMM037994C39]) due to an (almost) complete lack of inwardly rectifying K^+^ current (*I*~K1~) ([@DMM037994C25]) and presence of the hyperpolarization-activated inward current (*I*~f~) ([@DMM037994C21]) and 'Ca^2+^ clock' ([@DMM037994C14]). For action potential (AP) measurements, we selected cells with a high beating rate (\>1 Hz) to evaluate the effects of CCh on beating frequency and cells with a low beating rate (\<1 Hz) to assess AP properties with and without CCh at a fixed pacing rate of 1 Hz. As reported previously ([@DMM037994C24]), RA-treated WT hiPSC-CMs displayed shorter APs with a lower plateau as compared to DMSO-treated WT hiPSC-CMs, both during spontaneous activity and when paced at 1 Hz, thus showing a more atrial-like AP morphology ([Fig. S2](Fig. S2)). In voltage-clamp experiments, we confirmed the presence of *I*~K,ACh~ in RA-treated WT hiPSC-CMs. By applying CCh, a robust current could be evoked in RA-treated and not in DMSO-treated WT hiPSC-CMs ([Fig. 1](#DMM037994F1){ref-type="fig"}B). This *I*~K,ACh~ deactivated upon rapid addition of the muscarinic antagonist atropine ([Fig. 1](#DMM037994F1){ref-type="fig"}B). Functional *I*~K,ACh~ effects on spontaneous activity were subsequently demonstrated by AP measurements in spontaneously fast-beating hiPSC-CMs. [Figure 1](#DMM037994F1){ref-type="fig"}C shows typical examples; effects on frequency and maximal diastolic potential (MDP) are summarized in [Fig. 1](#DMM037994F1){ref-type="fig"}D and E, respectively. In RA-treated hiPSC-CMs, but not in DMSO-treated hiPSC-CMs, application of CCh caused a significant slowing of spontaneous activity due to hyperpolarization of the MDP and a slower diastolic depolarization rate. Thus, RA-treated hiPSC-CMs display an atrial-like phenotype with functional presence of *I*~K,ACh~ in line with previous observations ([@DMM037994C5]; [@DMM037994C24]), confirming that these cells are indeed suitable to study the electrophysiological effects of the Gβ5-S81L variant on *I*~K,ACh~. Fig. 1.**Application of retinoic acid (RA) to differentiating hiPSCs results in cardiomyocytes (CMs) that exhibit a robust acetylcholine-activated K^+^ current (*I*~K,ACh~).** (A) Transcript expression of genes in RA-treated hiPSC-CMs relative to expression in DMSO-treated hiPSC-CMs. Data are mean±s.e.m. of three biological replicates, normalized to *TBP*. RA treatment enhanced expression of the genes *KCNJ3*, *NPPA* and *NR2F2*. \**P*\<0.05 (two-sided *t*-tests). (B) Typical *I*~K,ACh~ traces in DMSO- and RA-treated hiPSC-CMs initiated by fast application of 100 µmol l^−1^ carbachol (CCh). After reaching steady state, addition of 1 mmol l^−1^ atropine achieves instant removal of CCh from muscarinic receptors and deactivation of the current. In DMSO-treated hiPSC-CMs, *I*~K,ACh~ was not detected, while RA-treated hiPSC-CMs all demonstrated a robust current (for average data, see [Fig. 2](#DMM037994F2){ref-type="fig"}). (C) Typical spontaneous action potentials (APs) of DMSO- and RA-treated hiPSC-CMs at baseline and upon addition of 10 µmol l^−1^ CCh. (D,E) Frequency of spontaneous APs (D: *n*=9, DMSO; *n*=10, RA) and maximal diastolic potential (MDP; E: *n*=9, DMSO; *n*=9, RA) of each cell at baseline and in the presence of CCh in DMSO- and RA-treated hiPSC-CMs. \**P*\<0.05 (two-way ANOVA). CCh reduces the AP frequency and causes significant MDP hyperpolarization in RA-treated, but not in DMSO-treated, hiPSC-CMs.Fig. 2.**Impact of the Gβ5-S81L variant on *I*~K,ACh~ in RA-treated hiPSC-CMs.** (A,B) Typical recordings (A) and average *I*~K,ACh~ density (B) in WT, S81L^het^ and S81L^homo^ hiPSC-CMs. Average *I*~K,ACh~ density is increased in S81L^homo^ hiPSC-CMs compared to WT and S81L^het^ hiPSC-CMs. \**P*\<0.05 (Kruskal--Wallis non-parametric test, followed by Bonferroni post-hoc analysis). (C,D) Time constant (τ) of *I*~K,ACh~ activation (C) and deactivation (D). (B-D) WT, *n*=27; S81L^het^, *n*=11; S81L^homo^, *n*=20 hiPSC-CMs. (E) Percentage of desensitization, measured as the percentage of *I*~K,ACh~ decrease at steady state upon continuous CCh application; WT, *n*=3; S81L^het^, *n*=6; S81L^homo^, *n*=5 hiPSC-CMs. (F) Transcript level of the genes involved in G-protein-coupled activation of *I*~K,ACh~. Data are mean±s.e.m. of three biological differentiation replicas and expression level of each gene in S81L^het^ and S81L^homo^ hiPSC-CMs is indicated as relative to its expression in WT hiPSC-CMs. No significant differences are observed in *KCNJ3*, *KCNJ5*, *RGS6* and *GNB5* transcript abundance across the WT, S81L^het^ and S81L^homo^ hiPSC-CMs.

*I*~K,ACh~ density is increased in S81L^homo^ hiPSC-CMs {#s2c}
-------------------------------------------------------

Having established the presence and relevance of *I*~K,ACh~ in our RA-treated hiPSC-CM model, we next compared the properties of *I*~K,ACh~ in the isogenic WT, S81L^het^ and S81L^homo^ hiPSC-CMs. [Figure 2](#DMM037994F2){ref-type="fig"}A shows typical examples of *I*~K,ACh~ measurements. *I*~K,ACh~ density was significantly higher in S81L^homo^ hiPSC-CMs compared to S81L^het^ and WT ([Fig. 2](#DMM037994F2){ref-type="fig"}B). Moreover, activation and deactivation time constants were not significantly different between groups ([Fig. 2](#DMM037994F2){ref-type="fig"}C,D). In addition, desensitization was similar between groups ([Fig. 2](#DMM037994F2){ref-type="fig"}E). No significant differences were observed in *KCNJ3*, *KCNJ5*, *RGS6* and *GNB5* transcript abundance across the WT, S81L^het^ and S81L^homo^ lines, indicating that the increased *I*~K,ACh~ density in S81L^homo^ hiPSC-CMs was not due to altered expression of these genes ([Fig. 2](#DMM037994F2){ref-type="fig"}F). Thus, homozygous presence of the Gβ5-S81L variant increases *I*~K,ACh~ density without changes in transcript levels or kinetics of the channel. Additionally, to exclude differences in CM-cell population composition, we evaluated the expression level of a CM sarcomeric structural gene, *TNNT2*, in the hiPSC-CMs from the different lines; no significant variation in *TNNT2* expression was observed in hiPSC-CMs across the three different genotypes ([Fig. S3](Fig. S3)). Also, no changes in the expression of *GNB1*, *GNB2* and *GNB4*, encoding the GIRK channel activatory β-subunits, was observed by reverse-transcription qPCR (RT-qPCR) ([Fig. S3](Fig. S3)). The expression of *GNB3* could not be assessed due to large variation. These results indicate that the observed increase in *I*~K,ACh~ does not seem to be dependent on the upregulation of these activatory β-subunits in Gβ5-S81L hiPSC-CMs.

S81L^homo^ hiPSC-CMs demonstrate a severe reduction in beating frequency upon CCh application {#s2d}
---------------------------------------------------------------------------------------------

Subsequently, we evaluated the effects of *I*~K,ACh~ activation on APs of WT, S81L^het^ and S81L^homo^ hiPSC-CMs. [Figure 3](#DMM037994F3){ref-type="fig"}A shows typical APs of spontaneously fast-beating hiPSC-CMs. Baseline AP parameters, i.e. in the absence of CCh, were similar between the three groups ([Fig. 3](#DMM037994F3){ref-type="fig"}A, and [Table S4](Table S4)), with the exception of a slightly higher spontaneous beating frequency in S81L^het^ hiPSC-CMs ([Fig. 3](#DMM037994F3){ref-type="fig"}B), indicating that baseline electrophysiological properties are unaffected by the Gβ5 S81L variant. *I*~K,ACh~ activation by CCh induced a reduction in spontaneous beating frequency in all three hiPSC-CM lines, which was much more pronounced in S81L^homo^ compared to WT hiPSC-CMs ([Fig. 3](#DMM037994F3){ref-type="fig"}A-C). In fact, 79% of the S81L^homo^ hiPSC-CMs became quiescent, while a quiescent state was reached in 44 and 10% of S81L^het^ and WT hiPSC-CMs, respectively ([Fig. 3](#DMM037994F3){ref-type="fig"}C). This main finding in S81L^homo^ hiPSC-CMs was confirmed in a second separate S81L^homo^ clone. In this second clone, 71% of the spontaneously beating S81L^homo^ hiPSC-CMs (*n*=7) became quiescent upon application of CCh. The higher amount of spontaneous activity cessation in S81L^homo^ hiPSC-CMs is in agreement with the observed increased *I*~K,ACh~ density. Owing to the termination of the spontaneous activity, however, we were unable to determine the effects on AP characteristics. Therefore, we also assessed the effects of *I*~K,ACh~ activation on APs in slow-beating hiPSC-CMs stimulated at an overdrive stimulus frequency of 1 Hz. In the absence of CCh, AP parameters were not different between WT, S81L^het^ and S81L^homo^ hiPSC-CMs ([Table 1](#DMM037994TB1){ref-type="table"}). This further shows that the Gβ5-S81L variant does not affect electrophysiological properties at baseline conditions. Upon addition of CCh, a significant MDP hyperpolarization was observed in all three groups ([Fig. 3](#DMM037994F3){ref-type="fig"}D; [Table 1](#DMM037994TB1){ref-type="table"}). In S81L^homo^ hiPSC-CMs, however, hyperpolarization was more pronounced as compared to the other two groups ([Fig. 3](#DMM037994F3){ref-type="fig"}E; [Table 1](#DMM037994TB1){ref-type="table"}). Furthermore, S81L^homo^ hiPSC-CMs displayed a more pronounced shortening of AP duration at 20% (APD~20~; [Table 1](#DMM037994TB1){ref-type="table"}). This suggests that the AP configuration is only seriously affected by *I*~K,ACh~ in hiPSC-CMs if *I*~K,ACh~ densities are large. Thus, while AP parameters in the absence of CCh were largely identical in the three hiPSC-CMs lines, the S81L^homo^ line demonstrated a more pronounced effect of CCh in terms of cellular hyperpolarization, AP shortening and slowing of spontaneous beating, which is in line with both the increased *I*~K,ACh~ density and the bradycardia exhibited only by homozygous Gβ5-S81L patients ([@DMM037994C20]). Fig. 3.**CCh induces more pronounced effects in S81L^homo^ compared to WT and S81L^het^ RA-treated hiPSC-CMs.** (A) Representative spontaneous APs at baseline (left) and upon 10 µmol l^−1^ CCh (right) in WT, S81L^het^ and S81L^homo^ RA-treated hiPSC-CMs. The slanted arrows near the APs in the presence of CCh indicate the last AP before cessation of spontaneous activity. (B) Average frequencies before and during application of CCh. CCh drastically reduces the spontaneous AP frequency of S81L^homo^ hiPSC-CMs. WT, *n*=10; S81L^het^, *n*=9; S81L^homo^, *n*=14. \*\**P*\<0.01 (two-way repeated measures ANOVA and post-hoc Bonferroni corrected pairwise comparison). (C) Proportion of WT, S81L^het^ and S81L^homo^ hiPSC-CMs that became quiescent upon application of CCh. WT, *n*=10; S81L^het^, *n*=9; S81L^homo^, *n*=14. \*\**P*\<0.01 (chi-square test, followed by Bonferroni corrected pairwise comparisons). (D) Representative APs (1 Hz overdrive stimulation) before and after the application of CCh. (E) Average maximal diastolic potential (MDP) at baseline and upon CCh in WT, S81L^het^ and S81L^homo^ RA-treated hiPSC-CMs (1 Hz overdrive stimulation). WT, *n*=17; S81L^het^, *n*=10; S81L^homo^, *n*=13. Effect of CCh on MDP is significantly more pronounced in S81L^homo^ hiPSC-CMs (*P*\<0.05 interaction effect CCh×genotype; two-way ANOVA). Table 1.**Action potential (AP) parameters in WT, S81L^het^ and S81L^homo^ hiPSC-CMs (paced at 1 Hz)**

Pharmacological *I*~K,ACh~ blockade rescues bradycardia in S81L^homo^ hiPSC-CMs and *gnb5-*knockout zebrafish {#s2e}
-------------------------------------------------------------------------------------------------------------

Given the observed increased *I*~K,ACh~ density in S81L^homo^ hiPSC-CMs, selective blockers of I(KACh) may provide a useful pharmacological treatment for patients with Gβ5 genetic defects. We tested this hypothesis in our hiPSC-CMs as well as *in vivo* in *gnb5*-knockout zebrafish that we generated previously ([@DMM037994C20]).

### *I*~K,ACh~ blockade in hiPSC-CMs {#s2e1}

We evaluated possible pharmacological rescue of the phenotype in S81L^homo^ hiPSC-CMs using the selective I(KACh) blocker XEN-R0703 ([@DMM037994C5]). [Figure 4](#DMM037994F4){ref-type="fig"}A shows typical examples of spontaneous activity at baseline (top panel), in the presence of CCh (middle panel) and in the presence of CCh and XEN-R0703 (bottom panel). Addition of 1 µmol l^−1^ XEN-R0703 in the presence of 10 µmol l^−1^ CCh resulted in an almost complete reversal of the effects of CCh on spontaneous activity. This indicates that the drug is efficient in reversing the enhanced reduction of automaticity in S81L^homo^ hiPSC-CMs ([Fig. 4](#DMM037994F4){ref-type="fig"}B). Fig. 4.**CCh induces an extreme slowing of spontaneous beating in S81L^homo^ hiPSC-CMs, which is largely suppressed by *I*~K,ACh~ blockade through XEN-R0703.** (A) Typical APs of an S81L^homo^ hiPSC-CM at baseline (top), upon application of 10 µmol l^−1^ CCh (middle), and upon addition of 1 µmol l^−1^ XEN-R0703 in the presence of 10 µmol l^−1^ CCh (bottom). (B) Effects of CCh and XEN-R0703 on spontaneous AP frequency in four S81L^homo^ hiPSC-CMs. \**P*\<0.05 (one-way repeated measures ANOVA followed by post-hoc Holm-Sidak test). XEN-R0703 restores the beating frequency of S81L^homo^ hiPSC-CMs to values similar to a baseline condition.

### *I*~K,ACh~ blockade in zebrafish {#s2e2}

We also tested XEN-R0703 *in vivo* in a *gnb5*-knockout zebrafish model that faithfully recapitulates the phenotypical spectrum of patients with pathogenic variants in *GNB5*, including bradycardia (for details, see [@DMM037994C20]). In short, CCh led to a strong decrease in HR in *gnb5*-knockout zebrafish, while little effect was observed in wild-type and sibling larvae ([@DMM037994C20]). To study the effect of XEN-R0703, HR of *gnb5*-knockout zebrafish was first recorded at baseline, then after the administration of 50 µmol l^−1^ XEN-R0703 or DMSO, and lastly after challenging larvae with 500 µmol l^−1^ CCh ([Fig. 5](#DMM037994F5){ref-type="fig"}B). The used concentrations are higher than in our patch-clamp assay because the zebrafish assay is considerably less sensitive ([@DMM037994C1]). While most larvae in the DMSO control group responded to CCh with a severe decrease in HR, larvae that were pretreated with XEN-R0703 had a markedly lower sensitivity to CCh ([Fig. 5](#DMM037994F5){ref-type="fig"}C). The response to CCh was calculated for each individual fish and the outcomes subdivided into categories of 0-25%, 26-50%, 51-75% and 76-100% decrease in HR. A 0-25% decrease in HR was considered physiological, whereas 26-100% was considered pathological. While 85% of the DMSO-treated *gnb5*-knockout fish showed a pathological decrease in HR, only 27% of fish pretreated with XEN-R0703 showed such a reduction ([Fig. 5](#DMM037994F5){ref-type="fig"}D). Together, these results demonstrate that *I*~K,ACh~ blockade largely rescues CCh-induced bradycardia in *gnb5*-knockout zebrafish. Fig. 5.**Effect of *I*~K,ACh~ blockade on heart rate (HR) in *gnb5*-knockout zebrafish.** (A) Experimental setup for high-speed imaging of the zebrafish heart. HR was recorded at 150 fps for 10 s. (B) Time schedule of drug treatment and CCh challenge in *gnb5-*knockout larvae. (C) Scatter dot plots with mean of HR of *gnb5-*knockout larvae 5 days post-fertilization at basal level, after treatment with 50 µmol l^−1^ XEN-R0703 or DMSO, and upon application of 500 µmol l^−1^ CCh. DMSO, *n*=13; XEN-R0703, *n*=22. \*\**P*\<0.01, \*\*\**P*\<0.001, \*\*\*\**P*\<0.0001 (two-way repeated measures ANOVA followed by Bonferroni corrected pairwise comparisons). (D) Percentage of *gnb5-*knockout larvae that responded to 500 µmol l^−1^ CCh with a decrease in HR of 0-25, 26-50, 51-75 or 76-100%. DMSO, *n*=13; XEN-R0703, *n*=22. Only 27% of *gnb5-*knockout larvae pretreated with XEN-R0703 displayed a pathological decrease in HR (51-75%, 76-100%), while over 80% of the not-pretreated *gnb5*-knockout larvae display the same decreased level of HR.

Predicted effects of the homozygous Gβ5-S81L variant in computational models of a SAN and an atrial cell {#s2f}
--------------------------------------------------------------------------------------------------------

To evaluate whether the observed increase in *I*~K,ACh~ density, associated with the homozygous variant, is the major contributor to the generation of excessive bradycardia, we conducted computer simulations using mathematical models of both a SAN pacemaker cell and an atrial cell ([@DMM037994C9]; [@DMM037994C23]). We implemented a threefold increase in *I*~K,ACh~ density, as observed in our experiments in S81L^homo^ hiPSC-CMs ([Fig. 2](#DMM037994F2){ref-type="fig"}B). In the WT human SAN model, application of ACh at a concentration of 10 nmol l^−1^ activated *I*~K,ACh~ and inhibited the hyperpolarization-activated current (*I*~f~), resulting in a decrease in depolarizing net current (*I*~net~) during diastole. Consequently, beating rate decreased from 74 to 58 bpm ([Fig. 6](#DMM037994F6){ref-type="fig"}A,B). However, implementing a threefold-increased *I*~K,ACh~ density, which simulates the homozygous Gβ5-S81L variant effects, resulted in a dramatic slowing of beating rate (from 74 to 17 bpm) ([Fig. 6](#DMM037994F6){ref-type="fig"}D,E). Additionally, *I*~K,ACh~ blockade, which simulates the pharmacological effects of XEN-R0703, largely, but incompletely, reversed the effects of ACh ([Fig. 6](#DMM037994F6){ref-type="fig"}C,F). These findings closely resemble those obtained in S81L^homo^ hiPSC-CMs, demonstrating that the threefold increase in *I*~K,ACh~ density is sufficient to induce the bradycardic phenotype. The reversal of the ACh effects by the simulated application of XEN-R0703 is incomplete because the inhibiting effect of ACh on *I*~f~ persists. The inhibiting effect of ACh/CCh on *I*~f~ may also explain the incomplete rescue of beating frequency by XEN-0703 in the mutant zebrafish and hiPSC-CMs. Fig. 6.**ACh induces more pronounced effects in S81L^homo^ compared to WT** **human SAN pacemaker cells in computer simulations.** (A-C) Spontaneous APs (blue lines) and associated net membrane current (*I*~net~, gray lines), hyperpolarization-activated 'funny current' (*I*~f~, green lines) and *I*~K,ACh~ (red lines) in a WT human SAN pacemaker cell at baseline (A), upon addition of 10 nmol l^−1^ ACh (B) and upon addition of 10 nmol l^−1^ ACh in the presence of XEN-R0703 (C). (D-F) Spontaneous APs and associated *I*~net~, *I*~f~ and *I*~K,ACh~ in an S81L^homo^ human SAN pacemaker cell at baseline (D), upon addition of 10 nmol l^−1^ ACh (E) and upon addition of 10 nmol l^−1^ ACh in the presence of XEN-R0703 (F).

One may argue that the Gβ5-S81L variant further suppresses pacemaker activity by reducing the excitability of the atrial tissue surrounding the SAN through a more pronounced membrane hyperpolarization by CCh/ACh, as we observed in S81L^homo^ hiPSC-CMs ([Fig. 3](#DMM037994F3){ref-type="fig"}E). This was assessed in simulations of a human atrial CM. At baseline, the wild-type model cell exhibits an MDP of −74.1 mV, which becomes hyperpolarized by 5.3 mV upon application of 10 nmol l^−1^ ACh ([Fig. 7](#DMM037994F7){ref-type="fig"}A, top, and C) as a result of the activation of *I*~K,ACh~ ([Fig. 7](#DMM037994F7){ref-type="fig"}A, bottom). Owing to the hyperpolarization, the threshold-stimulus current amplitude increases by 29% (from 14.6 pA/pF at baseline to 18.9 pA/pF) ([Fig. 7](#DMM037994F7){ref-type="fig"}D). After implementing the threefold increase in *I*~K,ACh~ density ([Fig. 7](#DMM037994F7){ref-type="fig"}B), the ACh-induced hyperpolarization is larger (7.2 mV), as is the increase in threshold-stimulus current (53%). Qualitatively similar observations are made at other concentrations of ACh ([Fig. 7](#DMM037994F7){ref-type="fig"}C,D). Thus, the homozygous Gβ5-S81L variant likely does not only slow pacemaker activity of SAN cells, but also reduces excitability of atrial cells, and, as such, contributes to the bradycardic phenotype in patients. Fig. 7.**ACh induces more pronounced AP effects in S81L^homo^ compared to WT human atrial myocytes in computer simulations.** (A,B) APs elicited at 1 Hz (top panels) and associated *I*~K,ACh~ (bottom panels) at baseline (dotted lines) and upon addition of 10 nmol l^−1^ ACh (solid lines) in WT (A) and S81L^homo^ (B) human atrial myocytes. The horizontal double-headed arrow in panel A indicates the ACh-induced shortening of AP duration. The 'wobbles' in the time course of *I*~K,ACh~ in panel B are caused by the N-shape of the *I*~K,ACh~ current-voltage relationship (insets). The slanted arrows in the insets point to the *I*~K,ACh~ reversal potential (*E*~K~) of −83.0 mV. (C,D) Shift in maximum diastolic potential (ΔMDP; C) and threshold stimulus current amplitude (D) at ACh concentrations ranging from 0.1 nmol l^−1^ to 1 µmol l^−1^. Note the logarithmic abscissa scale.

DISCUSSION {#s3}
==========

Genetic variants in *GNB5*, encoding Gβ5, have been linked to an autosomal recessive multisystem disorder that includes severe bradycardia at rest. The mechanism by which inherited genetic variation in *GNB5* causes bradycardia has remained unexplored. We here conducted electrophysiological studies in hiPSC-CMs that were genome-edited for the Gβ5-S81L variant to uncover the cellular mechanism underlying the bradycardia. We demonstrated that this variant causes a more pronounced slowing of beating rate by means of an increase in *I*~K,ACh~ density in response to cholinergic stimulation. Furthermore, we showed that this effect in hiPSC-CMs, as well as the effect of cholinergic-induced bradycardia in *gnb5*-knockout zebrafish, can be rescued by the specific *I*~K,ACh~ blocker XEN-R0703.

The cholinergic-gated K^+^ channel I(KACh) is involved in the negative chronotropic effect of the parasympathetic nervous system on HR ([@DMM037994C46]). It is an inwardly rectifying K^+^ channel ([@DMM037994C33]), and its activation results in an outward current leading to membrane hyperpolarization, AP shortening and slowing of beating rate ([@DMM037994C6]). The increased *I*~K,ACh~ density that we observed in S81L^homo^ hiPSC-CMs in response to cholinergic stimulation is thus a plausible explanation for the more pronounced slowing of beating rate and hyperpolarization we observed in these cells. Besides SAN cells, I(KACh) is also expressed in atrial CMs ([@DMM037994C7]), which raises the possibility that the increase in *I*~K,ACh~ as a consequence of Gβ5-S81L homozygosity may also contribute to bradycardia during increased vagal tone by reducing the excitability of the atrium. Decreased atrial excitability favors SAN exit block due to source-to-sink mismatch, eventually resulting in SAN pauses and bradycardia ([@DMM037994C13]). Indeed, the computer simulation studies that we conducted in an atrial CM model revealed a decreased excitability in cells in which the experimentally observed increase in *I*~K,ACh~ was implemented. Thus, apart from a direct effect on intrinsic pacemaker function, a more pronounced atrial hyperpolarization due to increased *I*~K,ACh~ may also contribute to the phenotype of homozygous Gβ5-S81L variant carriers. The fact that the defect associated with the Gβ5-S81L variant in hiPSC-CMs became apparent only upon cholinergic stimulation is in line with clinical findings. Patients homozygous for this variant suffer from a severe reduction of minimum HR (dependent on the parasympathetic tone), while maximum HR (chronotropic competence) is normal ([@DMM037994C20]). Furthermore, the finding that S81L^het^ hiPSC-CMs exhibit a similar *I*~K,ACh~ density and a similar response to CCh compared to WT hiPSC-CMs is in line with the unaffected heterozygous carriers ([@DMM037994C20]).

The binding of ACh to M~2~ muscarinic receptors triggers the activation of heterotrimeric G-proteins that dissociate into Gα-GTP and Gβγ subunits. While Gβ1-β4/γ complexes function to activate GIRK channels, Gβ5 has an inhibitory effect on these channels ([@DMM037994C16]). Gβ5 associates with RGS proteins of the R7 family, with RGS6 being the most abundant RGS in CMs. Gβ5-RGS complexes promote the hydrolysis of Gα-GTP to Gα-GDP, which then reassociates with Gβ1-β4/γ, likely relieving the activatory effect of Gβ1-β4/γ on the GIRK channel ([@DMM037994C35]). In a heterologous model of neuronal dopamine-receptor-mediated signaling, Shamseldin and colleagues showed that Gβ5-S81L leads to loss of function of Gβ5-RGS complexes \[acting as GTPase-activating proteins (GAPs) on Gα-GTP\], which presumably decreases the inhibitory reassociation of Gα-GDP with the βγ complexes during the termination response ([@DMM037994C34]). This would be in agreement with our observed increase in *I*~K,ACh~ density in the S81L^homo^ hiPSC-CMs. Conversely, a decreased rate of *I*~K,ACh~ deactivation was previously reported in both *Rgs6^−/−^* and *Gnb5^−/−^* mice ([@DMM037994C29]; [@DMM037994C47]; [@DMM037994C48]). However, the mechanism by which decreased deactivation rate of *I*~K,ACh~ affects HR in the absence of changes in density remains unclear. In the present study, we did not find kinetic changes in *I*~K,ACh~ as a consequence of the Gβ5-S81L variant. Notwithstanding, the augmented *I*~K,ACh~ that we observe is in line with the HR-reducing effect of the variant in patients with the mutation, as substantiated by our computer simulations.

*I*~K,ACh~ augmentation as a disease mechanism is also operative during atrial fibrillation ([@DMM037994C27]). *I*~K,ACh~ blockers have been developed to treat atrial fibrillation, although so far with disappointing results ([@DMM037994C28]). We demonstrated the potential of the *I*~K,ACh~ blocker XEN-R0703 by showing an almost complete rescue of the CCh-triggered decrease in beating frequency in S81L^homo^ hiPSC-CMs and by demonstrating rescue of CCh-induced bradycardia *in vivo* in *gnb5*-knockout zebrafish. Therefore, as previously suggested in mice ([@DMM037994C26]), our current study provides a possible new application for *I*~K,ACh~ blockers as a therapy for bradycardia in patients carrying mutations in *GNB5*, which may substitute or postpone pacemaker treatment.

hiPSC-CMs have become increasingly used to study ion channel variants causing inherited arrhythmia syndromes ([@DMM037994C3]; [@DMM037994C12]). Yet, differentiation protocols that have been used thus far in disease modeling generate primarily ventricular-like CMs ([@DMM037994C5]). We here investigated for the first time the effects of a human genetic variant in a signal transduction component utilizing a specific differentiation protocol that enriches for hiPSC-CMs expressing I(KACh), a channel that is active in SAN and atrial cells. This cellular model enabled us to study the effect of genetic variation in a component of a G protein-coupled receptor signaling cascade that impacts on ion channel function, rather than genetic variation within the ion channel itself, further underscoring the potential of this model. The introduction of the genetic variant in both the heterozygous and the homozygous state allowed us to compare the effect of different states of the variant, which matched the phenotype observed in heterozygous and homozygous S81L^homo^ carriers.

While the effects of the mutation on *I*~K,ACh~ are in agreement with the bradycardia phenotype of the patients, we have not studied the effect of the Gβ5-S81L variant in 'pacemaker-like' cells derived from hiPSCs ([@DMM037994C4]; [@DMM037994C30]). Furthermore, we focused on the effects of the Gβ5-S81L variant on intrinsic CM electrophysiological properties. However, *GNB5* is also expressed in neurons. Therefore, we cannot exclude the possibility of an effect of the variant on the beating rate through its effect in central or peripheral neurons. Finally, baseline AP properties were not different between groups, suggesting that the Gβ5-S81L variant does not affect ion currents at baseline. However, we cannot exclude effects on other ion currents that are modulated by CCh that may contribute to the bradycardic phenotype as well. Nonetheless, our modeling study demonstrated that the effect of the variant on *I*~K,ACh~ density is the main contributor to the reduction of the beating rate at the CM level and that blockade of the channel almost completely reverses the bradycardic phenotype.

We studied for the first time the cellular electrophysiological consequences of human genetic variation in *GNB5*. We demonstrated that the Gβ5-S81L variant in the homozygous state results in an increased *I*~K,ACh~ density upon muscarinic receptor stimulation and excessive slowing of spontaneous activity, a plausible mechanism for the bradycardia observed in the patients. Pharmacological *I*~K,ACh~ blockade rescues the phenotype in a cellular and an *in vivo* model, pointing to a possible therapy for bradycardia in patients carrying pathogenic variants in *GNB5*.

MATERIALS AND METHODS {#s4}
=====================

Genetic modification and differentiation of hiPSC lines into CMs {#s4a}
----------------------------------------------------------------

The study was approved by the Medical Ethics Committee of the Amsterdam UMC, location AMC (NL30225.018.09), and the University Medical Center Göttingen (Az 21/1/11). Written informed consent was obtained from the control individual from whom the hiPSC line was generated. The (*GNB5* c.242C\>T) Gβ5-S81L variant was introduced in the heterozygous or homozygous state into a previously characterized control hiPSC line ([@DMM037994C8]) by means of CRISPR/Cas9-based genome editing, according to a previously published protocol ([@DMM037994C32]). Briefly, we designed the *GNB5*-targeting gRNA sequence close to the single-nucleotide variant of interest ([Fig. S1B](Fig. S1B) and [Table S3](Table S3)) and cloned it into the pSPCas9(BB)-2a-GFP vector. Next, 4 µg of the gRNA-expressing vector and 4 µg of a single-strand oligodeoxynucleotide (ssODN) carrying: (1) the c.242C\>T mutation, (2) a total of 96 nucleotides of homologous sequence flanking the mutation site, and (3) a synonymous mutation that generates a *Hin*dIII restriction site ([Fig. S1B](Fig. S1B)), were delivered into the hiPSCs by nucleofection using the Lonza Amaxa 2b Nucleofector Device and the Stem Cell Nucleofector I Kit according to manufacturers' protocols ([Fig. S1A](Fig. S1A)). Restriction analysis of a PCR fragment defined by the *GNB5*-screen primers ([Table S1](Table S1)) was used to verify the presence of cells carrying the homologous recombination event in the whole population of transfected cells. GFP^+^ transfected cells that had internalized the gene-editing machinery were subsequently selected by fluorescent-activated cell sorting (FACS) and seeded at a low density (limiting dilution) to achieve monoclonal growth. A total of 96 separate clones were isolated mechanically, transferred into separate wells of a 96-well plate and expanded. Of these, 86 clones could be screened by Sanger sequencing for the presence of the *GNB5* mutation, a region of approximately 1000 nucleotides surrounding the gRNA target site. Nine clones were homozygous, two were heterozygous, 73 exhibited a mixed genetic profile \[e.g. indels; these included clones that were heterozygous (one clone) and homozygous (12 clones) at the nucleotide of interest\] and two clones contained a wild-type sequence. Heterozygous and homozygous clones carrying the desired S81L *GNB5* mutation were further expanded and cryo-stored. Clones with the desired genotype for further functional analysis were randomly picked from those available. Furthermore, using the CRISPR Finder online tool ([@DMM037994C11]), we identified three putative off-target sequences of the gRNA used ([Table S3](Table S3)). Sanger sequencing of these regions (primers in [Table S1](Table S1)) in the clones that were used in the functional studies did not reveal any sequence variant differences. Additionally, in order to exclude the possibility that a large deletion occurred on one of the two alleles at the targeted region (that, due to hemizygosity, could mimic the homozygous state on the DNA sequence read) we demonstrated that the heterozygous SNPs (rs28437132 and rs28409853, present in the original hiPSC line) were maintained within the same PCR product as the *GNB5* variant.

The original and generated hiPSC lines tested negative for mycoplasma contaminations. However, they were not recently authenticated by STR analysis. The generated isogenic hiPSC lines were subject to quality control including the evaluation of expression of the pluripotency markers TRA1-81, OCT-4, NANOG and SSEA4 by immunocytochemistry ([Fig. S1D,E](Fig. S1D,E) and [Table S2](Table S2)) as described previously ([@DMM037994C40]). Karyotype analysis was performed by the COBRA Fish technique ([@DMM037994C36]) for the WT and S81L^het^ hiPSC line and by G-banding for the S81L^homo^ hiPSC line ([Fig. S1F,G](Fig. S1F,G)).

HiPSCs were differentiated into CMs that robustly express I(KACh) using a previously described protocol in chemically defined medium and serum-free and feeder-free conditions ([@DMM037994C18]). One µmol l^−1^ all-trans-retinoic acid (RA; Sigma) was applied during day 4-7 of differentiation to promote acquisition of atrial-like fate and expression of the I(KACh) channel ([@DMM037994C5]; [@DMM037994C24]). A metabolic selection-based enrichment for hiPSC-CMs was used by applying glucose-depleted culture medium containing 4 mmol l^−1^ lactate during day 20-26 of differentiation ([@DMM037994C37]). For electrophysiological experiments, hiPSC-CM cultures were enzymatically dissociated into single cells and plated at a low density on Matrigel-coated coverslips ([@DMM037994C25]). All experiments were performed on cells from at least three independent differentiation replicas.

RT-qPCR {#s4b}
-------

RNA was isolated from the three isogenic hiPSC lines by using the Macherey-Nagel NucleoSpin RNA II isolation kit following the manufacturer\'s instructions. RNA (500 ng) was retro-transcribed using SuperScript II Reverse Transcriptase (Life Technologies) and oligo dT primers. To determine transcript abundance, quantitative PCR (qPCR) was conducted with SYBR Green on a Roche LightCycler 480 Real-Time PCR System. RNA samples were obtained from three biological differentiation replicas with triplicate measurements (technical replicas). Gene expression levels were analyzed using the LinReg PCR program ([@DMM037994C31]). *TBP* (TATA binding protein) was used as a reference gene. Primers are listed in [Table S1](Table S1).

Cellular electrophysiology in hiPSC-CMs {#s4c}
---------------------------------------

### Data acquisition {#s4c1}

*I*~K,ACh~ and APs were measured using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA, USA). Voltage control, data acquisition and analysis were realized with custom software. Pipettes (resistance 2-3 MΩ) were pulled from borosilicate glass capillaries (Harvard Apparatus, UK). Cell membrane capacitance (*C*~m~) was calculated and potentials were corrected for calculated liquid junction potentials ([@DMM037994C2]). Signals were low-pass-filtered with a cut-off of 5 kHz, and digitized at 40 and 20 kHz for APs and *I*~K,ACh~, respectively.

### *I*~K,ACh~ measurements {#s4c2}

*I*~K,ACh~ was measured at 21±0.2°C using the ruptured patch-clamp technique. Bath solution contained (in mmol l^−1^): 145 KCl, 1.0 MgCl~2~, 1.8 CaCl~2~, 10 glucose, 5 HEPES, pH 7.4 (KOH). Pipettes were filled with solution containing (in mmol l^−1^): 105 K-gluc, 20 KCl, 5 NaCl, 1 MgCl~2~, 10 BAPTA (pre-dissolved in KOH), 5 MgATP, 0.3 Na-GTP, 10 HEPES, pH 7.2 (NMDG-OH). *I*~K,ACh~ was elicited at −50 mV by rapidly applying 100 µmol l^−1^ CCh (Sigma) using a puffer pipette system in close proximity to the patched cell. *I*~K,ACh~ deactivation time kinetics were measured in the presence of 1 mmol l^−1^ of atropine, a muscarinic receptor antagonist. Current density was calculated by dividing the CCh-elicited current by *C*~m~. Time dependence of activation and deactivation were determined by fitting the mono-exponential functions *I*/*I*~max~=A×\[1-exp(-t/τ)\] and *I*/*I*~max~=A×exp(-t/τ), respectively, in which τ is the time constant of activation and deactivation, respectively; *I* and *I*~max~ are current (mA); *A* is amplitude; and *t* is time (seconds). Desensitization was defined as the percentage of current decay at steady state during continuous exposure to CCh. Cells that virtually lacked *I*~K,ACh~ were excluded from analysis. The proportion of excluded cells was similar in all groups.

### AP measurements {#s4c3}

APs were recorded at 36±0.2°C using the amphotericin-perforated patch-clamp technique and solutions as described previously ([@DMM037994C5]; [@DMM037994C24]; [@DMM037994C25]; [@DMM037994C42]). APs were elicited at an overdrive stimulus frequency of 1 Hz with 3-ms 1.2× threshold current pulses through the patch pipette. APs were recorded under control conditions and after 4-5 min of application of 10 µmol l^−1^ CCh. We analyzed cycle length, MDP, AP amplitude (APA), AP plateau amplitude (APA~plateau~; measured 20 ms after initiation of the AP upstroke), maximum AP upstroke velocity (*V*~max~), and AP duration at 20, 50 and 80% repolarization (APD~20~, APD~50~ and APD~80~, respectively). Parameters from ten consecutive APs were averaged.

### hiPSC-CM selection for assessment of CCh effect on AP {#s4c4}

Two populations of cells were included, one with a beating frequency \>1 Hz and another population with a beating frequency \<1 Hz. The first population was used to assess the effects of CCh on beating frequency (shown in [Fig. 3](#DMM037994F3){ref-type="fig"}A,B). Since a large proportion of cells became quiescent upon CCh application, the effects on AP properties could not be evaluated. Therefore, we also selected a population of cells that exhibited a beating rate \<1 Hz, which were paced at a fixed rate of 1 Hz. The results of the latter population are shown in [Fig. 3](#DMM037994F3){ref-type="fig"}D,E and in [Table 1](#DMM037994TB1){ref-type="table"}.

Heart rate analysis in *gnb5*-knockout zebrafish {#s4d}
------------------------------------------------

Zebrafish experiments were conducted in accordance with the local ethical guidelines and approved by the Ethics Committee of the Royal Netherlands Academy of Arts and Sciences. Fishes were housed under standard conditions as previously described ([@DMM037994C44]). Fish with a homozygous loss-of-function mutation in *gnb5a* and a heterozygous loss-of-function mutation in *gnb5b* (*gnb5a*^−/−^ *gnb5b*^+/−^) were crossed to obtain double-knockout mutants (*gnb5a*^−/−^ *gnb5b*^−/−^; referred to as *gnb5* knockout) as described previously ([@DMM037994C20]). Embryos at 5 days post-fertilization were embedded in 0.3% agarose (UltraPure, Thermo Fisher Scientific) prepared in E3 medium containing 16 mg ml^−1^ Tricaine. Measurements were performed at 28°C using an inverted light microscope with climate chamber and a high-speed CCD camera (Hamamatsu Photonics K.K., Hamamatsu City, Japan). HR was analyzed using ImageJ (National Institutes of Health, Bethesda, MD, USA).

Computer simulations {#s4e}
--------------------

The spontaneous electrical activity of a single human SA nodal pacemaker cell was simulated using the comprehensive mathematical model that was recently developed by Fabbri et al. ([@DMM037994C9]). In this Fabbri-Severi model, ACh does not only activate the ACh-activated K^+^ current (*I*~K,ACh~), but also inhibits the hyperpolarization-activated 'funny current' (*I*~f~), through a hyperpolarizing shift in its voltage dependence of activation (thus shifting the half-activation voltage of *I*~f~ to a more negative value). Furthermore, ACh inhibits the L-type Ca^2+^ current (*I*~Ca,L~) and the sarco/endoplasmic reticulum Ca^2+^-ATPase (SERCA pump), which regulates Ca^2+^ uptake into the sarcoplasmic reticulum. Under control conditions, the simulated administration of 10 nmol l^−1^ ACh leads to a 21% reduction in pacemaking rate from 74 to 58 bpm. Of note, the inhibition of *I*~f~ and activation of *I*~K,ACh~ are the major determinants of this rate slowdown, whereas the inhibiting effects on *I*~Ca,L~ and the SERCA pump only play a minor role ([@DMM037994C9]).

For simulations of a single human atrial cell, we used the model by [@DMM037994C23]. The latter model, which is also known as the 'human atrial myocyte with new repolarization' (hAMr) model, was selected because it includes well-validated equations for *I*~K,ACh~ ([@DMM037994C22]). APs were elicited with a 2-ms ≈50% suprathreshold stimulus current at a frequency of 1 Hz. The threshold-stimulus current amplitude was determined by increasing the stimulus current amplitude in 0.1-pA/pF steps until a train of 100 APs could successfully be elicited. To prevent slow drifts in ion concentrations, the intracellular Na^+^ and K^+^ concentrations were fixed, as were the cleft ion concentrations.

The CellML code of both models, as available from the CellML Model Repository ([@DMM037994C19]), was edited and run in version 0.9.31.1409 of the Windows-based Cellular Open Resource (COR) environment ([@DMM037994C10]). In both models, the S81L^homo^ mutation was simulated through a threefold increase in the conductance of I(KACh), based on the experimental observations shown in [Fig. 2](#DMM037994F2){ref-type="fig"}. All simulations were run for a sufficiently long time, i.e. for the duration of a train of 200 APs, to reach steady-state behavior.

Statistical analyses {#s4f}
--------------------

Statistical analysis was performed in IBM SPSS statistics 24 and GraphPad Prism 7. Data are presented as mean±s.e.m., unless stated otherwise. For non-normally distributed parameters, data are presented as boxplots, in which boxes represent lower quartile, median and upper quartile, and whiskers 1.5× interquartile range. Parameters were tested for normal distribution and equality of variance with the Shapiro-Wilk and Levene\'s test, respectively. In case of normally distributed data, two-sided *t*-tests or paired *t*-tests were performed for two groups and one-way ANOVA, followed by post-hoc Holm-Sidak tests for \>2 groups. In case of a non-normal distribution, Mann--Whitney *U*-tests or Wilcoxon rank tests were used for two groups and Kruskal--Wallis tests, followed by Bonferroni corrected pairwise comparisons, for \>2 groups. To test for differences in proportions, a chi-square test was used. In hiPSC-CMs, drug effects and effects of CCh were tested by one-way or two-way repeated measures ANOVA, respectively, followed by Holm-Sidak post-hoc tests or Bonferroni corrected pairwise comparisons, respectively. In zebrafish, the effect of XEN-R0703 was evaluated by two-way repeated measures ANOVA, followed by post-hoc Bonferroni corrected pairwise comparisons. *P*\<0.05 defines statistical significance.
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